OneSource Specialty Pharma Limited (NSE: ONESOURCE) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Sterile Product Division (SPD) facility in Bengaluru, with a ‘Voluntary Action Indicated’ (VAI) classification. This follows an inspection conducted from June 22 to June 30, 2026. This development highlights the company’s commitment to maintaining high standards of quality, regulatory compliance, and operational excellence.

Regulatory Milestone

The EIR with VAI classification signifies a regulatory milestone for OneSource. Neeraj Sharma, Managing Director & CEO, commented, “We are pleased to receive the EIR with VAI classification from the USFDA for our SPD facility. This outcome reflects our continued dedication to quality and compliance across our operations.”

Strategic Importance

The SPD facility plays a crucial role in OneSource’s sterile manufacturing capabilities, enabling the company to support the evolving needs of its global partners. This achievement adds to OneSource’s robust regulatory track record as it continues to build a globally competitive CDMO platform.

Future Outlook

As OneSource advances its capabilities in drug-device combinations, biologics, sterile injectables, and soft gelatin capsules, this milestone positions the company for continued growth and success in the pharmaceutical manufacturing sector. The company remains focused on delivering efficient, end-to-end solutions to its global clientele.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Onesource falls 14.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 232.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 14.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Onesource Specialty Pharma Limited.

Wanbury Limited (NSE: WANBURY) is pleased to announce that its manufacturing facility at Tanuku, Andhra Pradesh, has successfully received the Good Manufacturing Practice (GMP) Compliance Certificate from Australia’s Therapeutic Goods Administration (TGA), the regulatory authority responsible for therapeutic goods in Australia. This certification marks an important milestone in Wanbury’s commitment to manufacturing excellence, stringent quality standards, and strengthening its presence in regulated international pharmaceutical markets.

Successful Inspection and Compliance

Following a successful inspection conducted by the TGA on 8–9 June 2026, the Australian regulatory authority confirmed that the manufacturing facility complies with the applicable Good Manufacturing Practice requirements outlined in the PIC/S Guide to Good Manufacturing Practice for Medicinal Products. The certificate covers the manufacturing of six Active Pharmaceutical Ingredients (APIs): Metformin Hydrochloride, Tramadol Hydrochloride, Sertraline Hydrochloride, Diphenhydramine Hydrochloride, Mefenamic Acid, and Paroxetine Hydrochloride Hemihydrate.

A Step Forward in Global Growth

This achievement reinforces Wanbury’s focus on building globally compliant manufacturing capabilities and expanding its footprint across international markets. Recognition by a stringent regulatory authority such as Australia’s TGA further strengthens the company’s quality credentials and its ability to serve customers and partners in regulated pharmaceutical markets. The certification represents another significant milestone in Wanbury’s journey towards operational excellence, regulatory compliance, and sustainable business growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 42.1% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock sits at 16% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.

Hikal Limited (NSE: HIKAL) announced today that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a Certificate of GMP Compliance to its active pharmaceutical ingredient (API) facility in Bengaluru. This certification confirms the facility’s adherence to Good Manufacturing Practice (GMP) requirements under the Mutual Recognition Agreement between the European Union and Switzerland. The certification follows successful inspections by Brazil’s ANVISA and Japan’s PMDA, reinforcing the site’s standing with leading global regulators.

Enhanced Global Regulatory Standing

The Swissmedic certification strengthens Hikal’s global regulatory standing and expands access to European and other regulated markets. This development is a significant step in the company’s strategy to diversify its geographic footprint in the pharmaceutical business, building resilience against geopolitical and trade uncertainties.

Strategic Importance

Commenting on the development, Mr. Sameer Hiremath, Chairman & Managing Director of Hikal Limited, stated: ‘The Swissmedic certification is a strong endorsement of the quality systems at our Bengaluru facility. It is an important step in expanding the global reach of our pharmaceutical business and opens new opportunities with customers in Europe and other regulated markets. Quality, compliance, and manufacturing excellence remain the foundation of our long-term customer partnerships.’ This recognition is part of Hikal’s broader strategy to enhance its global presence and cater to a wider customer base across regulated markets.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 60% of its 52-week range with RSI at 48. In other words, neither side has a clear edge right now. The stock holds up despite -5.4% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Hikal Limited.